-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IVIG-PEG in Primary Humoral Immune Deficiencies
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IVIG-PEG in Primary Humoral Immune Deficiencies report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.IVIG-PEG in Primary Humoral Immune Deficiencies Drug Details:IVIG-PEG is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IONIS-FB-LRx in Geographic Atrophy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IONIS-FB-LRx in Geographic Atrophy report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.IONIS-FB-LRx in Geographic AtrophyDrug Details:IONIS-FB-LRx is under development for the treatment of geographic...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Axatilimab in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Axatilimab in Solid Tumor report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Axatilimab in Solid Tumor Drug Details:Axatilimab (SNDX-6352) is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Axatilimab in Graft Versus Host Disease (GVHD)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Axatilimab in Graft Versus Host Disease (GVHD) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Axatilimab in Graft Versus Host Disease (GVHD) Drug Details:Axatilimab (SNDX-6352)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Livmoniplimab in Oral Cavity (Mouth) Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Livmoniplimab in Oral Cavity (Mouth) Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Livmoniplimab in Oral Cavity (Mouth) Cancer Drug Details: Livmoniplimab (ABBV-151)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Alpha-1 Proteinase Inhibitor (Human) in Emphysema
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Alpha-1 Proteinase Inhibitor (Human) in EmphysemaDrug Details:Alpha1-proteinase inhibitor human (Prolastin, Trypsone, Pulmolast, Lynspad) also known as...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pembrolizumab in Colon Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pembrolizumab in Colon Tumor report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pembrolizumab in Colon Tumor Drug Details: Pembrolizumab (Keytruda) is an antineoplastic immunomodulating...
-
Sector Analysis
Acute Myeloid Leukemia (AML) Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and Forecast to 2032
Acute Myeloid Leukemia (AML) Market Report Overview The acute myeloid leukemia (AML) market in the eight major markets (8MM: the US, France, Germany, Italy, Spain, the UK, Japan, and China) was $2.3 billion in 2022. Steady growth is anticipated at a CAGR of more than 4% throughout the forecast period as the number of AML patients continues to climb and new therapies arrive in the 8MM. The AML market research report offers an overview of AML, including epidemiology, symptoms, diagnosis,...
-
Company Profile
Syndax Pharmaceuticals Inc – Company Profile
Syndax Pharmaceuticals Inc (Syndax) is a biopharmaceutical company that discovers, develops and commercializes therapies for multiple cancer indications. The company’s product portfolio includes SNDX-5613, a novel orally menin-MLL1 inhibitor used for the treatment of MLLr or mNPM1 acute leukemias; and SNDX-6352 (Axatilimab), a colony stimulating factor 1 receptor (CSF-1R) to treat chronic graft versus host disease (cGVHD). It is also evaluating entinostat (SNDX-275), a class I HDAC inhibitor against multiple solid tumors. Syndax product candidate are also used for the...
Add to Basket -
Product Insights
Bile Duct Cancer (Cholangiocarcinoma) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Bile Duct Cancer Pipeline Drugs Market Report Overview Bile duct cancer (cholangiocarcinoma) are tumors that occur in the bile duct. Symptoms include discomfort in the tummy area (abdomen), loss of appetite, high temperatures (fevers), and weight loss. Treatment includes chemotherapy and radiation therapy. The Bile Duct Cancer drugs in development market research report provides comprehensive information on the therapeutics under development for Bile Duct Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of...